National Brain Tumor Society (NBTS) offers our congratulations to President-elect Joe Biden and Vice President-elect Kamala Harris. President-elect Biden, more so than any other president in U.S. history, personally understands the devastating nature of brain tumors following the loss of his son, Beau, to glioblastoma. He and his wife, Dr. Jill Biden, care deeply about improving the future for cancer patients and caregivers, and we look forward to working together in the coming years to conquer and cure brain tumors, once and for all.
“Through his previous work on the Biden Cancer Moonshot and the Biden Cancer Initiative, we know that President-elect Biden keenly recognizes the issues, challenges, and opportunities facing the cancer research and healthcare enterprises,” says W.K. Alfred Yung, MD, distinguished scientific advisor to NBTS. “The brain tumor community, like the cancer community at large, will need his support and leadership to propel science forward and ensure affordable access to the full range of specialized healthcare services that brain tumor patients and families desperately need.”
As it has with every Administration, NBTS will be at the table working in a bipartisan fashion with the executive branch, as well as the new Congress, to advocate for the needs of the brain tumor community. From COVID-19’s impact on brain tumor patients to the broader national and global effort to cure brain tumors and all cancers, NBTS is committed to working with the Biden administration to ensure patients and caregivers are able to receive care and treatment grounded in the best science.
“We offer to the Biden transition team and the Administration our collective experience, partnership, and passion to make this decade one that produces breakthroughs in medical research and delivers cures and quality of life,” says David Arons, JD, chief executive officer of NBTS. “We stand ready to continue the fight against cancer with President-elect Biden, his transition team, and his administration to create real, tangible change for the brain tumor community in the years to come.”